INTU vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Intuit Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-16.
Intuit Inc. · Technology
$279.70
+45.0% upside to fair value
Grade A
High Quality
VS
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
QuantHub Verdict
INTU has more upside to fair value
(+45.0%).
INTU trades at a lower forward P/E
(16.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTU |
JNJ |
| Current Price |
$279.70 |
$253.85 |
| Fair Value Estimate |
$405.56 |
$198.76 |
| Upside to Fair Value |
+45.0%
|
-21.7%
|
| Market Cap |
$76.5B |
$611.1B |
| Forward P/E |
16.9x
|
29.3x
|
| EV / EBITDA |
11.2x
|
19.2x
|
| Price / Sales |
3.7x
|
6.3x
|
| Price / FCF |
9.9x
|
34.3x
|
| Revenue Growth YoY |
+10.4%
|
+9.9%
|
| Gross Margin |
81.0%
|
69.1%
|
| Operating Margin |
27.5%
|
26.9%
|
| Return on Equity |
23.3%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
10.08%
|
2.91%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Intuit Inc. is a leading technology company specializing in software applications for financial management, including popular products like TurboTax and QuickBooks. The company demonstrates high business quality with a durable competitive moat supported by strong brand recognition, high gross margins of 81%, and a robust return on equity of 23.3%. Despite a moderate revenue growth of 10.4% and ea…
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Accumulation Zones
| Metric |
INTU |
JNJ |
| Zone Low |
$304.17 |
$149.07 |
| Zone High |
$344.73 |
$168.95 |
| In Buy Zone? |
Yes
|
No
|